Drug Trial Radar · NCT00478556
Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
Last checked: Nov 19, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Aug 2007
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GE Healthcare
- First posted
- May 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
Conditions
- Healthy
Interventions
OmnipaqueDrug
Oral CT contrast
GastroviewDrug
Oral CT contrast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Preferred Contrast AgentTime frame: 1 Day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Kirklin Clinic
Birmingham, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.